Karolinska Development

Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations. Today, the portfolio consists of 34 projects, of which 14 are in clinical development.

 

Karolinska Development presents at "Avanza Banks Börsdag",
November 29, 2011 
Click to listen to the webcast (only in Swedish)

 

  Axelar-ESMO-poster_2011-09-26.png Axelar reports good safety profile of AXL1717 in Phase I/II in cancer patients


VIEW PORTFOLIO BY THERAPEUTIC AREA:
Click to view portfolio progress